CleminorextonA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Sponsor:

Centessa Pharmaceuticals (UK) Limited

Code:

NCT07598708

Conditions

Narcolepsy Type 1

Narcolepsy Type 2

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

cleminorexton

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Centessa Pharmaceuticals (UK) Limited on 2026-08-11.